| 1.06 0.01 (0.95%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.48 | 1-year : | 1.65 |
| Resists | First : | 1.26 | Second : | 1.41 |
| Pivot price | 1.18  |
|||
| Supports | First : | 1.01 | Second : | 0.84 |
| MAs | MA(5) : | 1.04 |
MA(20) : | 1.2 |
| MA(100) : | 1.48 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.6 |
D(3) : | 3.6 |
| RSI | RSI(14): 36.7 |
|||
| 52-week | High : | 4.48 | Low : | 1.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRIS ] has closed above bottom band by 22.9%. Bollinger Bands are 57% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.14 - 1.15 | 1.15 - 1.15 |
| Low: | 1.04 - 1.04 | 1.04 - 1.05 |
| Close: | 1.05 - 1.06 | 1.06 - 1.07 |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Tue, 09 Dec 2025
Curis Provides Updated Data from its Frontline AML Triplet Study - PR Newswire
Thu, 20 Nov 2025
Curis, Inc. (NASDAQ:CRIS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - simplywall.st
Fri, 14 Nov 2025
Curis to Present at Upcoming 30th Annual SNO Meeting - PR Newswire
Sun, 09 Nov 2025
Analysts Have Been Trimming Their Curis, Inc. (NASDAQ:CRIS) Price Target After Its Latest Report - Yahoo Finance
Sat, 08 Nov 2025
Curis, Inc. (NASDAQ:CRIS) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 06 Nov 2025
Curis Provides Third Quarter 2025 Business Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 6.9 (%) |
| Held by Institutions | 35.6 (%) |
| Shares Short | 107 (K) |
| Shares Short P.Month | 127 (K) |
| EPS | -3.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.15 |
| Profit Margin | 0 % |
| Operating Margin | -218.1 % |
| Return on Assets (ttm) | -61.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 8.3 % |
| Gross Profit (p.s.) | -1.56 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -2.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.33 |
| PEG Ratio | 0 |
| Price to Book value | -0.93 |
| Price to Sales | 1.17 |
| Price to Cash Flow | -0.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|